MAP2K7 and telomere syndrome: Temsirolimus is being investigated as a single agent in patients with STS or GIST93 as well as patients with recurrent or persistent uterine cancer.94 Also, temsirolimus is being evaluated in combination studies with vinorelbine and cyclophosphamide in patients with recurrent or refractory rhabdomyosarcoma,95 and with selumetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, in patients with metastatic, recurrent, or locally advanced unresectable STS.93